CN105294619A - Novel diterpene compound and preparation method and medical application thereof - Google Patents
Novel diterpene compound and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105294619A CN105294619A CN201510694237.9A CN201510694237A CN105294619A CN 105294619 A CN105294619 A CN 105294619A CN 201510694237 A CN201510694237 A CN 201510694237A CN 105294619 A CN105294619 A CN 105294619A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- preparation
- extract
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a novel diterpene compound and a preparation method and medical application thereof. The compound is reported for the first time and is novel in structure. The compound can be obtained by being extracted from dried sculellaria barbata herb and conducting separation and purification. Research proves that the compound can remarkably restrain melanoma cell growth, the cell population and the concentration of the compound (I) are decreased dependently, and the compound can be used for being developed into medicine for treating melanomas.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry herb of Herba Scutellariae Barbatae, be separated obtain a kind of and there is diterpene compound for the treatment of melanoma effect and preparation method thereof.
Background technology
Herba Scutellariae Barbatae Scutellariabarbata, have another name called and head grass, narrow leaf Indian Skullcap Herb, for Labiatae Scutellaria per nnial herb, be often born in the moist ground such as pond, the edge of a field, mountain stream, Zhejiang, Jiangsu, Anhui, Henan, Sichuan, Guangdong, Fujian, Shaanxi etc. are economized all has distribution.Herba Scutellariae Barbatae is cold in nature, and taste is pungent, bitter, and have the effects such as clearing heat and detoxicating, loose stasis of blood hemostasis, inducing diuresis to remove edema, being used for the treatment of furuncle swelling toxin, swelling and pain in the throat, traumatic pain, oedema, jaundice, snake bite and insect sting etc., is conventional herbal medicine among the people.
The chemical constitution study of Herba Scutellariae Barbatae is published in " the Herba Scutellariae Barbatae chemical constitution study bulletin " of " herbal medicine " entirely first appeared in Wang Zhao in 1981, so far researchist goes out hundreds of monomeric compound by modern plants chemical research technology isolation identification from Herba Scutellariae Barbatae, mainly flavonoid and diterpenes, also has the compositions such as alkaloid, steroidal, phenols, tannin and polysaccharide.Flavonoid compound is one of main component of Herba Scutellariae Barbatae, and structure contains the broad varietys such as flavones, flavanone, flavanonol, cinnamophenone.Diterpene is the another kind of main chemical compositions of Herba Scutellariae Barbatae, is also current research emphasis.Structure is mainly neo clerodane diterpenoids, comprises Herba Scutellariae Barbatae diterpene (scutellone) class, Herba Scutellariae Barbatae lactone (scuterivulactone) class, Herba Scutellariae Barbatae alkaloid (Scutebarbatine) class and rivularin (barbatin) class etc.Activity experiment shows, and Diterpenoid Alkaloids has good cytotoxicity, effectively can suppress the growth of various human tumour cell.
Modern pharmacology activity research shows, Herba Scutellariae Barbatae has good anti-tumor activity, is therefore widely used in the assisting therapy of the malignant tumours such as primary hepatocarcinoma, lung cancer, cervical cancer as antitumor and anti-inflammatory drug.Wherein scutellarin, wogonin, apigenin, luteolin etc. have good antibacterial, anti-oxidant and anti-tumor activity.In addition, Herba Scutellariae Barbatae also blocks the keeping of human body to tumour cell by Tumor suppression vasculogenesis, thus reaches the object of inhibition tumor cell propagation and transfer.Except above-mentioned activity, Herba Scutellariae Barbatae also have protect the liver, antiviral and diuresis and stone expeling isoreactivity.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry herb of Herba Scutellariae Barbatae, be separated obtain a kind of there is diterpene compound for the treatment of melanoma effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry herb of Herba Scutellariae Barbatae is pulverized by (a), extract with 75 ~ 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 75% ethanol elution, 8 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 90:1,65:1,30:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
Further, described alcohol heat reflux extracts the alcohol concn adopted is 80%.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in preparation treatment melanoma medicine.
The application of described pharmaceutical composition in preparation treatment melanoma medicine.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value;
Fig. 3 is BrdU Immunofluorescence test Cell proliferation results.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry herb (8kg) of Herba Scutellariae Barbatae is pulverized by (a), (25L × 3 time) are extracted with 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (351g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 75% ethanol elution, 8 column volumes again, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract (133g); C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 90:1 (8 column volumes), the methylene chloride-methanol gradient elution of 65:1 (8 column volumes), 30:1 (6 column volumes), 15:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (31g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 25:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (17g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (31mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z499.1904, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
25h
32o
9, degree of unsaturation is 10.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-1 (4.79, t, J=2.4), H-2 (1.64, m), H-2 (1.84, m), H-3 (1.11, m), H-3 (1.75, m), H-6 (5.25, s), H-8 (2.07, d), H-9 (2.61, t, J=12.0), H-11 (1.35, m), H-11 (1.99, m), H-15 (5.93, s), H-17 (5.54, d, J=1.8), H-17 (5.32, d, J=1.8), H-18 (1.07, s), H-19 (1.03, s), H-20 (1.11, s), 1-OAc (2.04, s), 6-OAc (2.14, s), 12-OCH
3(3.02, s), 5-OH (2.89, br, s), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125MHz): 74.9 (CH, 1-C), 21.7 (CH
2, 2-C), 32.1 (CH
2, 3-C), 38.3 (C, 4-C), 79.2 (C, 5-C), 77.0 (CH, 6-C), 202.4 (C, 7-C), 48.1 (CH, 8-C), 36.5 (CH, 9-C), 43.8 (C, 10-C), 35.4 (CH
2, 11-C), 106.6 (C, 12-C), 166.0 (C, 13-C), 139.4 (C, 14-C), 115.1 (CH, 15-C), 169.3 (C, 16-C), 115.7 (CH
2, 17-C), 30.2 (CH
3, 18-C), 24.3 (CH
3, 19-C), 16.4 (CH
3, 20-C), 168.8 (C, 1-OAc), 20.7 (CH
3, 1-OAc), 172.1 (C, 6-OAc), 21.7 (CH
3, 6-OAc), 49.6 (CH
3, 12-OCH
3), carbon atom mark is see Fig. 1.IR spectrum shows carbonyl (1757cm
-1) signal, and UV spectrum maximum absorption wavelength is at 212nm place, shows that this compound contains α, β-unsaturated butenolide part.Olefinic proton signals δ H5.93 (H-15, s) and be positioned at the carbon signal δ C166.0 (C-13) of low field, 115.1 (C-15) and 169.3 (C-16) also demonstrate that the existence of this structure.In addition again in conjunction with three methyl signals δ H1.07 (H
3-18, s), 1.03 (H
3-19, s) He 1.11 (H
3-20, s), can show that this compound is a tetracyclic diterpene compound containing butenolide structural unit.In HMBC spectrum, H-1 (δ H4.79, t, J=2.4Hz) and-OCOCH
3(δ C168.8); H-6 (δ H5.25, s) and-OCOCH
3(δ C172.1); 12-OCH
3with the dependency of C-12 (δ C106.6), (δ H3.02, s) shows that C-1 and C-6 position is connected with acetoxyl group, C-12 is connected with methoxyl group.In HSQC and HMBC spectrum, proton signal δ H5.54 (d, J=1.8Hz) and 5.32 (d, J=1.8Hz) with carbon signal (δ C115.7, C-17) be directly connected, and with the dependency of C-14 (δ C139.4) and C-13 (δ C166.0) long distance, show to be connected with double bond between C-14 and C-17.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
People A375 melanoma cell strain is given by Third Military Medical University.Compound (I) is made by oneself, and preparation method is shown in that embodiment 1, HPLC normalization method purity is greater than 98%.DMEM substratum, 0.25% pancreatin purchased from American Gibco company.MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt; Methyl thiazoly tetrazolium assay), DMSO (dimethyl sulfoxide (DMSO)), BrdU purchased from American Sigma company.Mouse-anti BrdU polyclonal antibody purchased from American ABcam company.Goat against murine two anti-purchased from American Cellsignaling company.AnnexinV-FITC/PI cell apoptosis detection kit purchased from American Promega company.
Constant temperature CO
2incubator, general refrigerator ,-80 degree refrigerators are U.S. Forma Products.Bechtop (Chinese Suzhou cleaning project company).Inverted microscope, inverted fluorescence microscope (olympus company).Electro-heating standing-temperature cultivator (Chinese Shanghai leap medical apparatus and instruments factory).Automatic microplate reader (Japanese Wako company).UV detector (Beckman company of the U.S.).J6-HC supercentrifuge (Beckman company of the U.S.).Low-temperature trace whizzer (German Eppendorf company).Vibration shaking table (Forma company of the U.S.).
Two, test method
1, cell cultures
1.1 cell recovery
Frozen A375 melanoma cell in liquid nitrogen container taken out, put into rapidly the warm water of 37 DEG C, shake makes it melt as early as possible (about lmin) gently.Then sucking-off cell suspension, joins in the centrifuge tube being added with 2mL substratum, blows and beats mixing gently, 800r/min, and centrifugal 5min discards upper strata substratum.After making cell suspension with the DMEM substratum 8mL of the mould G/ Streptomycin sulphate containing 10%FBS and 1%, be seeded in 10cm culture plate.Then 5%CO is placed in
2, cultivate in 37 DEG C of constant incubators.
1.2 passage
Basis of microscopic observation cytogamy degree can go down to posterity when reaching 80%-90%.First use 2mLPBS washed cell 2 times, then add the pancreatin lmL of 0.25%.Horizontal wave and culture dish gently, makes Digestive system can cover the surface of cell, is then placed in 37 DEG C of incubators and digests about lmin.See that cell rounding bounces back under being placed in microscope, then add rapidly the substratum termination digestion that 1mL contains FBS.Blow and beat to cell dispersal even gently, then go down to posterity according to 1:2 or 1:3 according to cell density, be re-seeded in new culture plate, be placed in 5%CO
2, cultivate in 37 DEG C of constant incubators.
1.3 cell cryopreservation
Get the cell that 1 dish is in logarithmic phase, trysinization is also collected in centrifuge tube, and the centrifugal 5min of 1000r/min, abandons supernatant.Then add lmL frozen storing liquid, dispel cell gently and make cell suspension, cell suspension is joined in the cryopreservation tube of 1.5mL.In the title of cryopreservation tube subscript clear-cells, shelf time, the name of preserver.First cryopreservation tube is put into 4 DEG C of refrigerators, place about 30min.Then be placed in-20 DEG C of refrigerators, place about 2h.Then be put in-80 DEG C of Ultralow Temperature Freezers to place and spend the night.Frozen cell was placed in the medium-term and long-term preservation of liquid nitrogen container in second day.
2, cell counting draws cell growth curve
(1) take the logarithm A375 melanoma cell in vegetative period, counting, adjustment cell density is 2 × 10
4/ mL.
(2) by cell suspension inoculation in 12 orifice plates, 1.5mL/ hole.
(3) after 12h, treat cell attachment, change 1mL plasma-free DMEM medium, and use 5 μm of ol/L compounds (I) and DMSO (for the compound (I) of DMSO dilution respectively, control DMSO concentration is below 1/1000, guarantee cell harmless) process, often organize cell and establish 3 parallel holes, be placed in 5%C02,37 DEG C of constant incubators are cultivated.
(4) stop cultivating respectively at 0h, 24h, 48h, 72h, 96h, collect each group of cell, add 0.25% tryptic digestion, centrifugal, resuspended.
(5) cell counting: draw cell suspension 10 μ L, add isopyknic phenol blue area and divide viable cell, draw 10 μ L mixed solutions and add in cell counting count board groove gently, ensure tight and bubble.Under inverted microscope, the cell count in counting periphery four block plaid, substitutes into formula: archeocyte suspension concentration (cell count/mL)=(cell count/4 of 4 block plaid) × 10
4× extension rate.
(6) calculate number of viable cells, draw cell growth curve.
3, mtt assay detects cell proliferation
(1) the A375 cell of taking the logarithm vegetative period, digestion, centrifugal, resuspended, counting, in adjustment cell suspension, the density of cell is 2 × 10
4/ mL.
(2) by each group of cell suspension inoculation in 96 well culture plates, the 200 every holes of μ L, often organize cell 3 parallel holes, establish blank control wells (only adding substratum) simultaneously.
(3) 12h is after cell attachment, changes 200 μ L plasma-free DMEM medium, and uses 5 μm of ol/L compounds (I) and DMSO process respectively.
(4) stopped cultivating respectively at 0,1,2,3,4 day.
(5) add Methyl thiazoly tetrazolium assay (MTT) the 20 μ L that concentration is 5mg/mL to every hole and continue culturing cell 4h.
(6) inhale the substratum abandoned in each aperture, add 200 μ LDMSO, microoscillator is vibrated 10min, and crystallisate is fully dissolved.
(7) return to zero with blank control wells, automatic microplate reader is adopted to measure the absorption photometric value (OD value) at 570nm place, each hole, ability of cell proliferation is represented with the OD value of correspondence, the each group of mean value getting 3 parallel holes, take time as transverse axis, with each absorbance for the longitudinal axis draws cell growth curve.
4, BrdU Immunofluorescence test cell proliferation
(1) creep plate is prepared: creep plate is put into 75% alcohol and soak 24h and disinfect.
(2) aseptic creep plate is placed in 24 well culture plates, the A375 melanoma cell in vegetative period of taking the logarithm, digestion, centrifugal, make cell suspension, 2 × 10
4cell/ hole, is inoculated in and is placed with in the hole of creep plate.
(3) 12h is after cell attachment, changes 1mL plasma-free DMEM medium, and uses 5 μm of ol/L compounds (I) and DMSO process respectively.
(4) after 72h, add 10 μ lBrdU (1mg/mL) in the medium, cultivate 1h for 37 DEG C.
(5) take out 24 orifice plates, wash 5min × 2 time with cold PBS, 4% paraformaldehyde fixed cell, room temperature 30min.
(6) PBS washes 5min × 3 time.
(7) 2mol/LHCl process, after room temperature 10min, 37 DEG C of 20min.
(8) the penetrating process in cell 1%Triton ×-100, washes 5min × 3 time.
(9) 10% lowlenthal serums are closed, room temperature, lh.
(10) BrdU monoclonal antibody (1:300 dilution) is added, 37 DEG C of 1.5h.
(11) l × PBST shakes and washes 5min × 3 time.
(12) add BrdU bis-anti-(1:300), after room temperature lucifuge 1h, l × PBST washes 3 times.
(13) DAPI staining fluid transfect cell core 15min.
(14) PBS washes 5min × 3 time.
(15) 1 anti-fluorescent quenching mounting liquid is added, neutral gum mounting, fluorescence microscopy Microscopic observation, photograph.
5, statistical study
Application SPSS17.0 statistical analysis software, adopt two independent samples t test and one-way analysis of variance to carry out data analysis, data X ± S represents, P<0.05 is for there being statistical significance.
Three, result and conclusion
Cellular form is observed and counting display, and with DMSO control group ratio, after compound (I) process A375 cell 24h, 48h, 72h, viable count significantly reduces and reaches 44.5%.The results are shown in Table 1 (with control group ratio
*p<0.05,
*p<0.01, lower same).
MTT result shows, and compound (I) can significantly suppress A375 cell proliferation, and OD value is that the decline of concentration (5 μm of ol/L, 10 μm of ol/L, 20 μm of ol/L) dependency reaches 27.3%, and difference has statistical significance.The results are shown in Table 2.
Compound (I) energy check melanin tumor cell proliferation is confirmed further by BrdU immunofluorescence dyeing, 5 μm of ol/L compound (I) process A375 cells are after 3 days, compared with contrast (26.07 ± 2.59%), experimental group BrdU positive cell percentage (7.55 ± 2.76%) significantly reduces (P=0.000).The results are shown in Figure 3 (* * P<0.01).
This experiment have detected the impact that compound (I) is bred melanoma cell, cell counting and MTT analytical results all prove that compound (I) can remarkable check melanin tumor cell growth, and cell count and compound (I) concentration are that dependency declines.After BrdU immunofluorescence dyeing also shows compound (I) process, BrdU positive cell percentage is significantly lower than control group, illustrates that compound (I) can suppress A375 melanoma cell to be bred.Compound (I) may be melanomatous efficient targeting medicine.
Table 1 compound (I) dose-dependent inhibition A375 cell proliferation (cell counting, unit: × l0
4/ mL) (
n=3)
| Group | 0h | 24h | 48h | 72h | 96h |
| DMSO | 2.87±0.23 | 4.72±0.30 | 7.36±0.13 | 7.56±0.39 | 8.04±0.27 |
| Compound (I)-5 μm of ol/L | 2.87±0.23 | 3.87±0.36* | 3.48±0.32** | 3.40±0.34** | 2.54±0.41** |
| Compound (I)-10 μm of ol/L | 2.87±0.23 | 2.36±0.28** | 2.95±0.37** | 1.56±0.36** | 0.89±0.26** |
Table 2 compound (I) dose-dependent inhibition A375 cell proliferation (mtt assay, OD570) (
n=3)
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry herb of Herba Scutellariae Barbatae is pulverized by (a), extract with 75 ~ 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 75% ethanol elution, 8 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 90:1,65:1,30:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
4. the preparation method of compound according to claim 2 (I), is characterized in that: it is 80% that described alcohol heat reflux extracts the alcohol concn adopted.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in preparation treatment melanoma medicine.
7. the application of pharmaceutical composition according to claim 5 in preparation treatment melanoma medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510694237.9A CN105294619A (en) | 2015-10-21 | 2015-10-21 | Novel diterpene compound and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510694237.9A CN105294619A (en) | 2015-10-21 | 2015-10-21 | Novel diterpene compound and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105294619A true CN105294619A (en) | 2016-02-03 |
Family
ID=55192535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510694237.9A Withdrawn CN105294619A (en) | 2015-10-21 | 2015-10-21 | Novel diterpene compound and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105294619A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105566300A (en) * | 2016-01-21 | 2016-05-11 | 李宇花 | Novel alkaloid compound and preparation method and medical application thereof |
| CN105566342A (en) * | 2015-12-22 | 2016-05-11 | 潘豪杰 | Novel diterpenoid for treating melanoma and preparation method thereof |
| CN107434764A (en) * | 2016-05-29 | 2017-12-05 | 戴明虎 | It is a kind of to be used to treat new triterpene compound of melanoma and preparation method thereof and medical usage |
-
2015
- 2015-10-21 CN CN201510694237.9A patent/CN105294619A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105566342A (en) * | 2015-12-22 | 2016-05-11 | 潘豪杰 | Novel diterpenoid for treating melanoma and preparation method thereof |
| CN105566300A (en) * | 2016-01-21 | 2016-05-11 | 李宇花 | Novel alkaloid compound and preparation method and medical application thereof |
| CN107434764A (en) * | 2016-05-29 | 2017-12-05 | 戴明虎 | It is a kind of to be used to treat new triterpene compound of melanoma and preparation method thereof and medical usage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105061456A (en) | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof | |
| CN105330674A (en) | New diterpenoid compound and preparation method and medical application thereof | |
| CN105061548A (en) | Novel withanolides compound and preparation method and medical application thereof | |
| CN105017276A (en) | Five-membered epoxy structure compound for treating pancreatic cancer | |
| CN105481881A (en) | Novel diterpene alkaloid compound and preparation method and medical application thereof | |
| CN105175481B (en) | A kind of highly oxidized diterpene compound and preparation method thereof and medical usage | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN105153187A (en) | New diterpenoid as well as preparation method and medical application thereof | |
| CN105294619A (en) | Novel diterpene compound and preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN104961791A (en) | Novel triterpene compound in potentilla anserina, and preparation method and application thereof | |
| CN105503999A (en) | Limonin compounds for treating melanoma and preparation method thereof | |
| CN105330717A (en) | Novel triterpenoid and preparation method and medical application thereof | |
| CN105330673A (en) | Novel limonin compound and preparation method and medical application thereof | |
| CN105218489A (en) | A kind of assorted terpene compound newly and preparation method thereof and medicinal use | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105566342A (en) | Novel diterpenoid for treating melanoma and preparation method thereof | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105418562A (en) | Diterpenoid compound used for treating the prostatic cancer and preparation method therefor | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105524063A (en) | Novel terpene indole alkaloid compound, and preparation method and medical application thereof | |
| CN105153263A (en) | New limonin compound as well as preparation method and medical application thereof | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160203 |